Clinical activity of crizotinib in lung adenocarcinoma harboring a HLA_AROS1 rearrangement: A case report

  • Authors:
    • Ryosuke Kinoshita
    • Makoto Nakao
    • Hiroko Kiyotoshi
    • Syuntaro Hayashi
    • Masahiro Sugihara
    • Yuya Hirata
    • Mamiko Kuriyama
    • Norihisa Takeda
    • Hideki Muramatsu
  • View Affiliations

  • Published online on: October 13, 2023     https://doi.org/10.3892/ol.2023.14102
  • Article Number: 515
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The benefits of crizotinib therapy in patients with tyrosine receptor kinase ROS proto‑oncogene 1 (ROS1)‑rearranged non‑small cell lung cancer (NSCLC) have been demonstrated. The present study reports a 47‑year‑old woman with lung adenocarcinoma harboring a rare HLA_AROS1 rearrangement with clinical response to crizotinib. To the best of our knowledge there have been no reports of HLA_AROS1‑rearranged lung cancer regarding clinical course and the efficacy of treatment with crizotinib. A good response to crizotinib therapy in the present case could be a reference for the treatment and prognosis of ROS1‑rearranged NSCLC with the same fusion partner. The current report will remind oncologists and pulmonologists to consider the importance of accurate multigene panel assays for detecting driver oncogenes in treating patients with NSCLC.
View Figures
View References

Related Articles

Journal Cover

December-2023
Volume 26 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kinoshita R, Nakao M, Kiyotoshi H, Hayashi S, Sugihara M, Hirata Y, Kuriyama M, Takeda N and Muramatsu H: Clinical activity of crizotinib in lung adenocarcinoma harboring a <em>HLA_A</em>‑<em>ROS1</em> rearrangement: A case report. Oncol Lett 26: 515, 2023.
APA
Kinoshita, R., Nakao, M., Kiyotoshi, H., Hayashi, S., Sugihara, M., Hirata, Y. ... Muramatsu, H. (2023). Clinical activity of crizotinib in lung adenocarcinoma harboring a <em>HLA_A</em>‑<em>ROS1</em> rearrangement: A case report. Oncology Letters, 26, 515. https://doi.org/10.3892/ol.2023.14102
MLA
Kinoshita, R., Nakao, M., Kiyotoshi, H., Hayashi, S., Sugihara, M., Hirata, Y., Kuriyama, M., Takeda, N., Muramatsu, H."Clinical activity of crizotinib in lung adenocarcinoma harboring a <em>HLA_A</em>‑<em>ROS1</em> rearrangement: A case report". Oncology Letters 26.6 (2023): 515.
Chicago
Kinoshita, R., Nakao, M., Kiyotoshi, H., Hayashi, S., Sugihara, M., Hirata, Y., Kuriyama, M., Takeda, N., Muramatsu, H."Clinical activity of crizotinib in lung adenocarcinoma harboring a <em>HLA_A</em>‑<em>ROS1</em> rearrangement: A case report". Oncology Letters 26, no. 6 (2023): 515. https://doi.org/10.3892/ol.2023.14102